Search

Your search keyword '"Ribaldone D.G."' showing total 37 results
Start Over Author "Ribaldone D.G."
37 results on '"Ribaldone D.G."'

1. A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium

Author

Mengoli, C., Aronico, N., Lepore, F., Broglio, G., Merli, S., Natalello, G., Alimenti, E., Scalvini, D., Muscarella, S., Agustoni, F., Pagani, A., Chiellino, S., Corallo, S., Musella, V., Cannizzaro, R., Vecchi, M., Caprioli, F., Gabbiadini, R., Dal Buono, A., Premoli, A., Locati, L.D., Buda, A., Contaldo, A., Schiepatti, A., Biagi, F., Morano, D., Cucè, M., Kotsakis, A., De Lisi, G., Lenti, M.V., Ribaldone, D.G., Borrelli de Andreis, F., Vernero, M., Barberio, B., De Ruvo, M., Savarino, E.V., Kav, T., Blesl, A., Franzoi, M., Gröchenig, H.P., Pugliese, D., Ianiro, G., Porcari, S., Cammarota, G., Gasbarrini, A., Spagnuolo, R., Ellul, P., Foteinogiannopoulou, K., Koutroubakis, I., Argyriou, K., Cappello, M., Jauregui-Amezaga, A., Demarzo, M.G., Silvestris, N., Armuzzi, A., Sottotetti, F., Bertani, L., Festa, S., Eder, P., Pedrazzoli, P., Lasagna, A., Vanoli, A., Gambini, G., Santacroce, G., Rossi, C.M., Delliponti, M., Klersy, C., Corazza, G.R., and Di Sabatino, A.

Published
2024
Full Text
View/download PDF

3. OC.04.7: A ONE-YEAR FOLLOW-UP STUDY ON CHECKPOINT INHIBITORINDUCED COLITIS: RESULTS FROM A EUROPEAN CONSORTIUM

Author

Lenti, M.V., primary, Broglio, G., additional, Ribaldone, D.G., additional, Schiepatti, A., additional, Vernero, M., additional, Cosentino, F., additional, Blesl, A., additional, Buda, A., additional, Croitoru, A., additional, Del Buono, A., additional, Aranzazu Jaurgeu, A., additional, Lasagna, A., additional, Carvalho, D., additional, Pugliese, D., additional, Langholz, E., additional, Dahl, E., additional, Savarino, E.V., additional, Agustoni, F., additional, De Andreis, F. Borrelli, additional, Caprioli, F., additional, Schaik, F., additional, Sottotetti, F., additional, Cammarota, G., additional, Ianiro, G., additional, Gröchenig, H.P., additional, Koutroubakis, I., additional, Geldolf, J., additional, Argyriou, K., additional, Foteinogiannopolou, K., additional, Bertani, L., additional, Lobaton Ortega, T., additional, Cappello, M., additional, Delliponti, M., additional, Demarzo, M.G., additional, Truyens, M., additional, Silvestris, N., additional, Ellul, J., additional, Cannizzaro, R., additional, Gabbiadini, R., additional, Pedrazzoli, P., additional, Spagnuolo, R., additional, Saglio, S., additional, Stroie, T.G., additional, Natalello, G., additional, Varallo, M., additional, La Torre, M.A., additional, Petrucci, C., additional, Klersey, C., additional, Corazza, G.R., additional, and Di Sabatino, A., additional

Published
2024
Full Text
View/download PDF

4. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY

Author

Viola, A., primary, Ventimiglia, M., additional, Sparacino, A., additional, D'Antonio, E., additional, Orlando, A., additional, De Vivo, S., additional, Pugliese, D., additional, Varca, S., additional, Scaldaferri, F., additional, Ribaldone, D.G., additional, Armandi, A., additional, Balestrieri, P., additional, Castiglione, F., additional, Savarino, E.V., additional, Cappello, M., additional, Viganò, C., additional, Mocci, G., additional, Allocca, M., additional, Principi, M.B., additional, Soriano, A., additional, Onali, S., additional, Bodini, G., additional, Riguccio, G., additional, Festa, S., additional, Bertani, L., additional, Checchin, D., additional, Caprioli, F., additional, and Fries, W., additional

Published
2024
Full Text
View/download PDF

8. Interferon gamma-induced protein 10 levels are associated with insulin resistant components in subjects with non-alcoholic fatty liver disease

Author

Guariglia, M., primary, Rosso, C., additional, Carli, F., additional, Caviglia, G.P., additional, Armandi, A., additional, Dileo, E., additional, Perez-Diaz-del-Campo, N., additional, Castelnuovo, G., additional, Abate, M.L., additional, Olivero, A., additional, Ribaldone, D.G., additional, Saracco, G.M., additional, Gastaldelli, A., additional, and Bugianesi, E., additional

Published
2023
Full Text
View/download PDF

9. Social jetlag and mediterranean diet adherence are associated to liver fibrosis in patients with non-alcoholic fatty liver disease

Author

Castelnuovo, G., primary, Caviglia, G.P., additional, Rosso, C., additional, Perez-Diaz-del-Campo, N., additional, Armandi, A., additional, Abdulle, A., additional, D'Amato, D., additional, Guariglia, M., additional, Poggiolini, I., additional, Olivero, A., additional, Abate, M.L., additional, Ribaldone, D.G., additional, Saracco, G.M., additional, and Bugianesi, E., additional

Published
2023
Full Text
View/download PDF

10. Echocardiography-based markers of subclinical cardiac dysfunction in individuals with Non-Alcoholic Fatty Liver Disease and preserved ejection fraction: Interim data from a prospective study

Author

Armandi, A., primary, Andreis, A., additional, Bellettini, M., additional, Caviglia, G.P., additional, Castelnuovo, G., additional, Poggiolini, I., additional, Rosso, C., additional, Del Campo, N. Perez Diaz, additional, Abdulle, A., additional, Gjini, K, additional, D'Amato, D., additional, Ribaldone, D.G., additional, De Ferrari, G.M., additional, Saracco, G.M., additional, Castagno, D., additional, and Bugianesi, E., additional

Published
2023
Full Text
View/download PDF

11. Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series

Author

Festa, S., Zerboni, G., Derikx, L.A.A.P., Ribaldone, D.G., Dragoni, G., Buskens, C., Dijkum, E.N. van, Pugliese, D., Panzuto, F., Krela-Kaźmierczak, I., Mintz, H.R., Shitrit, A.B., Chaparro, M., Gisbert, J.P., Kopylov, U., Teich, N., Vainer, E., Nagtegaal, I.D., Hoentjen, F., Garcia, M.J., Filip, R., Foteinogiannopoulou, K., Koutroubakis, I.E., Argollo, M., Wanrooij, R.L.J. van, Laja, H., Lobaton, T., Truyens, M., Molnar, T., Savarino, E., Aratari, A., Papi, C., Goren, I., Festa, S., Zerboni, G., Derikx, L.A.A.P., Ribaldone, D.G., Dragoni, G., Buskens, C., Dijkum, E.N. van, Pugliese, D., Panzuto, F., Krela-Kaźmierczak, I., Mintz, H.R., Shitrit, A.B., Chaparro, M., Gisbert, J.P., Kopylov, U., Teich, N., Vainer, E., Nagtegaal, I.D., Hoentjen, F., Garcia, M.J., Filip, R., Foteinogiannopoulou, K., Koutroubakis, I.E., Argollo, M., Wanrooij, R.L.J. van, Laja, H., Lobaton, T., Truyens, M., Molnar, T., Savarino, E., Aratari, A., Papi, C., and Goren, I.

Abstract

Item does not contain fulltext, BACKGROUND: Gastroenteropancreatic neuroendocrine neoplasms [GEP-NENs] have rarely been reported in association with inflammatory bowel diseases [IBDs]. METHODS: An ECCO COllaborative Network For Exceptionally Rare case reports project [ECCO-CONFER] collects cases of GEP-NENs diagnosed in patients with IBD. RESULTS: GEP-NEN was diagnosed in 100 IBD patients; 61% female, 55% Crohn's disease, median age 48 years (interquartile range [IQR] 38-59]). The most common location was the appendix [39%] followed by the colon [22%]. Comprehensive IBD-related data were available for 50 individuals with a median follow-up of 30 months [IQR 11-70] following NEN diagnosis. Median duration of IBD at NEN diagnosis was 84 months [IQR 10-151], and in 18% of cases NEN and IBD were diagnosed concomitantly. At diagnosis, 20/50 were stage-I [T1N0M0], and 28/50 were graded G1 [ki67 ≤2%]. Incidental diagnosis of NEN and concomitantly IBD diagnosis were associated with an earlier NEN stage [p = 0.01 and p = 0.02, respectively]. Exposure to immunomodulatory or biologic therapy was not associated with advanced NEN stage or grade. Primary GEP-NEN were more frequently found in the segment affected by IBD [62% vs 38%]. At the last follow-up data, 47/50 patients were alive, and only two deaths were related to NEN. CONCLUSIONS: In the largest case series to date, prognosis of patients with GEP-NEN and IBD seems favourable. Incidental NEN diagnosis correlates with an earlier NEN stage, and IBD-related therapies are probably independent of NEN stage and grade. The association of GEP-NEN location and the segment affected by IBD may suggest a possible role of inflammation in NEN tumorigenesis.

Published
2022

12. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.

Author

Yanai, H., Kagramanova, A., Knyazev, O., Sabino, J., Haenen, S., Mantzaris, G.J., Mountaki, K., Armuzzi, A., Pugliese, D., Furfaro, F., Fiorino, G., Drobne, D., Kurent, T., Yassin, S., Maharshak, N., Castiglione, F., Sire, R. de, Nardone, O.M., Farkas, K., Molnar, T., Krznaric, Z., Brinar, M., Chashkova, E., Livne Margolin, M., Kopylov, U., Bezzio, C., Bar-Gil Shitrit, A., Lukas, M., Chaparro, M., Truyens, M., Nancey, S., Lobaton, T., Gisbert, J.P., Saibeni, S., Bacsúr, P., Bossuyt, P., Schulberg, J., Hoentjen, F., Viganò, C., Palermo, A., Torres, J., Revés, J., Karmiris, K., Velegraki, M., Savarino, E., Markopoulos, P., Tsironi, E., Ellul, P., Calviño Suárez, C., Weisshof, R., Ben-Hur, D., Naftali, T., Eriksson, C., Koutroubakis, I.E., Foteinogiannopoulou, K., Limdi, J.K., Liu, E., Surís, G., Calabrese, E., Zorzi, F., Filip, R., Ribaldone, D.G., Snir, Y., Goren, I., Banai-Eran, H., Broytman, Y., Amir Barak, H., Avni-Biron, I., Ollech, J.E., Dotan, I., haroni Golan, M. A, Yanai, H., Kagramanova, A., Knyazev, O., Sabino, J., Haenen, S., Mantzaris, G.J., Mountaki, K., Armuzzi, A., Pugliese, D., Furfaro, F., Fiorino, G., Drobne, D., Kurent, T., Yassin, S., Maharshak, N., Castiglione, F., Sire, R. de, Nardone, O.M., Farkas, K., Molnar, T., Krznaric, Z., Brinar, M., Chashkova, E., Livne Margolin, M., Kopylov, U., Bezzio, C., Bar-Gil Shitrit, A., Lukas, M., Chaparro, M., Truyens, M., Nancey, S., Lobaton, T., Gisbert, J.P., Saibeni, S., Bacsúr, P., Bossuyt, P., Schulberg, J., Hoentjen, F., Viganò, C., Palermo, A., Torres, J., Revés, J., Karmiris, K., Velegraki, M., Savarino, E., Markopoulos, P., Tsironi, E., Ellul, P., Calviño Suárez, C., Weisshof, R., Ben-Hur, D., Naftali, T., Eriksson, C., Koutroubakis, I.E., Foteinogiannopoulou, K., Limdi, J.K., Liu, E., Surís, G., Calabrese, E., Zorzi, F., Filip, R., Ribaldone, D.G., Snir, Y., Goren, I., Banai-Eran, H., Broytman, Y., Amir Barak, H., Avni-Biron, I., Ollech, J.E., Dotan, I., and haroni Golan, M. A

Abstract

Item does not contain fulltext, BACKGROUND: Endoscopic-post-operative-recurrence [ePOR] in Crohn's disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor [anti-TNF] therapy to vedolizumab [VDZ] and ustekinumab [UST] in a real-world setting. METHODS: A retrospective multicentre study of CD-adults after curative ICR on early prophylaxis was undertaken. ePOR was defined as a Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD ≥ 6. Multivariable logistic regression was used to evaluate risk factors, and inverse probability treatment weighting [IPTW] was applied to compare the effectiveness between agents. RESULTS: The study included 297 patients (53.9% males, age at diagnosis 24 years [19-32], age at ICR 34 years [26-43], 18.5% smokers, 27.6% biologic-naïve, 65.7% anti-TNF experienced, 28.6% two or more biologics and 17.2% previous surgery). Overall, 224, 39 and 34 patients received anti-TNF, VDZ or UST, respectively. Patients treated with VDZ and UST were more biologic experienced with higher rates of previous surgery. ePOR rates within 1 year were 41.8%. ePOR rates by treatment groups were: anti-TNF 40.2%, VDZ 33% and UST 61.8%. Risk factors for ePOR at 1 year were: past-infliximab (adjusted odds ratio [adj.OR] = 1.73 [95% confidence interval, CI: 1.01-2.97]), past-adalimumab [adj.OR = 2.32 [95% CI: 1.35-4.01] and surgical aspects. After IPTW, the risk of ePOR within 1 year of VDZ vs anti-TNF or UST vs anti-TNF was comparable (OR = 0.55 [95% CI: 0.25-1.19], OR = 1.86 [95% CI: 0.79-4.38]), respectively. CONCLUSION: Prevention of ePOR within 1 year after surgery was successful in ~60% of patients. Patients treated with VDZ or UST consisted of a more refractory group. After controlling for confounders, no differences in ePOR risk were seen between anti-TNF prophylaxis and other groups.

Published
2022

13. T.03.3 FECAL SMALL NON-CODING RNAS AND MICROBIOME CHARACTERIZE PATIENTS WITH CELIAC DISEASE

Author

Francavilla, A., primary, Ferrero, G., additional, Pardini, B., additional, Tarallo, S., additional, Zanatto, L., additional, Caviglia, G.P., additional, Sieri, S., additional, Grioni, S., additional, Francescato, G., additional, Stalla, F., additional, Guiotto, C., additional, Crocellà, L., additional, Astegiano, M., additional, Bruno, M., additional, Vineis, P., additional, Ribaldone, D.G., additional, and Naccarati, A., additional

Published
2022
Full Text
View/download PDF

14. T.06.2 MANAGEMENT AND OUTCOME OF CHECK-POINT INHIBITORINDUCED COLITIS: A MULTICENTRE RETROSPECTIVE STUDY

Author

Lenti, M.V., primary, Ribaldone, D.G., additional, Vernero, M., additional, De Andreis, F. Borrelli, additional, Savarino, E., additional, Zingone, F., additional, Sottotetti, F., additional, Cappello, M., additional, Brinch, D., additional, Silvestris, N., additional, Rossi, C.M., additional, Santacroce, G., additional, Klersy, C., additional, De Grazia, F., additional, Pagani, A., additional, Muscarella, S., additional, Brunetti, O., additional, De Ruvo, M., additional, Premoli, A., additional, Pedrazzoli, P., additional, Corazza, G.R., additional, and Di Sabatino, A., additional

Published
2022
Full Text
View/download PDF

17. OC.09.2 VITAMIN D-RELATED GENETICS AS PREDICTOR OF RESPONSE TO ADALIMUMAB IN CROHN’S DISEASE

Author

Cusato, J., primary, Bertani, L., additional, Antonucci, M., additional, Tomasello, C., additional, Caviglia, G.P., additional, Dibitetto, S., additional, Massano, A., additional, Mangia, M., additional, Mula, J., additional, Ceccarelli, L., additional, Costa, F., additional, Zanzi, F., additional, Astegiano, M., additional, Ribaldone, D.G., additional, and D’avolio, A., additional

Published
2021
Full Text
View/download PDF

18. AF.52 LONG-TERM OUTCOME OF ACUTE SEVERE ULCERATIVE COLITIS RESPONSIVE TO INTRAVENOUS STEROID: A MULTICENTER IG-IBD STUDY

Author

Festa, S., primary, Scribano, M.L., additional, Aratari, A., additional, Bezzio, C., additional, Principi, M., additional, Pugliese, D., additional, Ribaldone, D.G., additional, Furfaro, F., additional, Mocci, G., additional, Spagnuolo, R., additional, Vernia, P., additional, Costa, F., additional, Cosintino, R., additional, De Biasio, F., additional, Saibeni, S., additional, Armuzzi, A., additional, and Papi, C., additional

Published
2021
Full Text
View/download PDF

19. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study

Author

Goessens, L., Colombel, J.F., Outtier, A., Ferrante, M., Sabino, J., Judge, C., Saeidi, R, Rabbitt, L., Armuzzi, A., Domenech, E., Michalopoulos, G., Cremer, A., García-Alonso, F.J., Molnar, T., Karmiris, K., Gecse, K., Oostrom, J. van, Löwenberg, M., Farkas, K., Atreya, R., Ribaldone, D.G., Selinger, C., Hoentjen, F., Bihin, B., Sebastian, S., Rahier, J.F., Goessens, L., Colombel, J.F., Outtier, A., Ferrante, M., Sabino, J., Judge, C., Saeidi, R, Rabbitt, L., Armuzzi, A., Domenech, E., Michalopoulos, G., Cremer, A., García-Alonso, F.J., Molnar, T., Karmiris, K., Gecse, K., Oostrom, J. van, Löwenberg, M., Farkas, K., Atreya, R., Ribaldone, D.G., Selinger, C., Hoentjen, F., Bihin, B., Sebastian, S., and Rahier, J.F.

Abstract

Item does not contain fulltext, BACKGROUND AND AIMS: Few data are available regarding the combination of biologics or small molecules in inflammatory bowel disease (IBD) patients. We report safety and efficacy of such combinations through a retrospective multicentre series. METHODS: Combination therapy was defined as the concomitant use of two biologics or one biologic with a small molecule. Patient demographics, disease characteristics and types of combinations were recorded. Safety was evaluated according to the occurrence of serious infection, opportunistic infection, hospitalisation, life-threatening event, worsening of IBD or immune-mediated inflammatory diseases (IMID), cancer and death. Efficacy was evaluated as the physician global assessment of the combination and comparison of clinical/endoscopic scores of IBD/IMID activity prior and during combination. RESULTS: A total of 104 combinations were collected in 98 patients. Concomitant IMID were present in 41 patients. Reasons for starting combination therapy were active IBD (67%), active IMID or extra-intestinal manifestations (EIM) (22%), both (10%) and unclassified in 1. Median duration of combination was 8 months (interquartile range 5-16). During 122 patient-years of follow-up, 42 significant adverse events were observed, mostly related to uncontrolled IBD. There were 10 significant infections, 1 skin cancer and no death. IBD disease activity was clinically improved in 70% and IMID/EIM activity in 81% of the patients. Overall, combination was continued in 55% of the patients. CONCLUSIONS: Combination of biologics and small molecules in patients with IBD and IMID/EIM seems to be a promising therapeutic strategy but is also associated with a risk of opportunistic infections or infections leading to hospitalisation in 10%.

Published
2021

21. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients

Author

Eliadou, E., Moleiro, J., Ribaldone, D.G., Astegiano, M., Rothfuss, K., Taxonera, C., Ghalim, F., Carbonnel, F., Verstockt, B., Festa, S., Maia, L., Berrozpe, A., Zagorowicz, E., Savarino, E., Ellul, P., Vavricka, S.R., Calvo, M., Koutroubakis, I., Hoentjen, F., Salazar, L.F., Callela, F., Pizarro, F.C., Soufleris, K., Sonnenberg, E., Cavicchi, M., Wypych, J., Hommel, C., Ghiani, A., Fiorino, G., Eliadou, E., Moleiro, J., Ribaldone, D.G., Astegiano, M., Rothfuss, K., Taxonera, C., Ghalim, F., Carbonnel, F., Verstockt, B., Festa, S., Maia, L., Berrozpe, A., Zagorowicz, E., Savarino, E., Ellul, P., Vavricka, S.R., Calvo, M., Koutroubakis, I., Hoentjen, F., Salazar, L.F., Callela, F., Pizarro, F.C., Soufleris, K., Sonnenberg, E., Cavicchi, M., Wypych, J., Hommel, C., Ghiani, A., and Fiorino, G.

Abstract

Contains fulltext : 220103.pdf (Publisher’s version ) (Closed access), BACKGROUND: Interstitial lung [ILD] disease and granulomatous lung disease [GLD] are rare respiratory disorders that have been associated with inflammatory bowel disease [IBD]. Clinical presentation is polymorphic and aetiology is unclear. METHODS: This was an ECCO-CONFER project. Cases of concomitant ILD or GLD and IBD, or drug-induced ILD/GLD, were collected. The criteria for diagnosing ILD and GLD were based on definitions from the American Thoracic Society and the European Respiratory Society and on the discretion of reporting clinician. RESULTS: We identified 31 patients with ILD. The majority had ulcerative colitis [UC] [n = 22]. Drug-related ILD was found in 64% of these patients, 25 patients [80.6%] required hospitalisation, and one required non-invasive ventilation. The causative drug was stopped in all drug-related ILD, and 87% of patients received systemic steroids. At follow-up, 16% of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms, and there were no data in 13%. One patient was referred for lung transplantation, and one death from lung fibrosis was reported. We also identified 22 GLD patients: most had Crohn's disease [CD] [n = 17]. Drug-related GLD was found in 36% of patients and 10 patients [45.4%] required hospitalisation. The causative drug was stopped in all drug-related GLD, and 81% of patients received systemic steroids. Remission of both conditions was achieved in almost all patients. CONCLUSIONS: ILD and GLD, although rare, can cause significant morbidity. In our series, over half of cases were drug-related and therefore focused pharmacovigilance is needed to identify and manage these cases.

Published
2020

25. T04.01.9 IMPACT OF ULCERATIVE COLITIS AND ITS ASSOCIATED DISEASE BURDEN ON ITALIAN PATIENTS: THE FIRST-YEAR ANALYSIS OF THE ICONIC STUDY

Author

Orlando, A., primary, Daperno, M., additional, Maconi, G., additional, Biancone, L., additional, Scribano, M.L., additional, Principi, M., additional, Burrelli Scotti, G., additional, Bodini, G., additional, Ribaldone, D.G., additional, Gemignani, L., additional, Gualberti, G., additional, and Fiorino, G., additional

Published
2020
Full Text
View/download PDF

28. P.01.32 PROBIOTIC SUPPLEMENTATION IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN ITALY: DATA FROM THE ITALIAN REGISTRY ON H. PYLORI TREATMENT

Author

Zagari, R.M., primary, Romiti, A., additional, Saracino, I.M., additional, Ribaldone, D.G., additional, Gigliotti, F., additional, Lella, F., additional, Avallone, L., additional, Annibale, B., additional, Hervoso, C. Marfinati, additional, Grande, G., additional, Luzza, F., additional, Broglia, L., additional, Gasbarrini, A., additional, Catanzaro, R., additional, Cannizzaro, R., additional, Nardone, G., additional, Panarese, A., additional, Del Vecchio Blanco, G., additional, Vaira, B., additional, Pellicano, R., additional, Ferrara, M., additional, Romano, M., additional, Conigliaro, R.L., additional, Stanghellini, V., additional, and Bazzoli, F., additional

Published
2019
Full Text
View/download PDF

29. OC.09.5 LONG TERM COLECTOMY RATE IN ACUTE SEVERE ULCERATIVE COLITIS. AN ITALIAN MULTICENTER IG-IBD STUDY

Author

Festa, S., primary, Scribano, M.L., additional, Pugliese, D., additional, Sarli, E., additional, Bezzio, C., additional, Principi, M.B., additional, Ribaldone, D.G., additional, Allocca, M., additional, Mocci, G., additional, Bodini, G., additional, Spagnuolo, R., additional, Vernia, P., additional, Mazzuoli, S., additional, Laino, G., additional, Barberio, B., additional, Zerboni, G., additional, Aratari, A., additional, and Papi, C., additional

Published
2019
Full Text
View/download PDF

30. P.01.14 CURRENT PRACTICE OF GASTROENTEROLOGISTS IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION IN ITALY: DATA FROM THE ITALIAN REGISTRY ON H. PYLORI TREATMENT

Author

Zagari, R.M., primary, Romiti, A., additional, Saracino, I.M., additional, Ribaldone, D.G., additional, Gigliotti, F., additional, Lella, F., additional, Avallone, L., additional, Annibale, B., additional, Hervoso, C. Marfinati, additional, Grande, G., additional, Luzza, F., additional, Broglia, L., additional, Gasbarrini, A., additional, Catanzaro, R., additional, Cannizzaro, R., additional, Nardone, G., additional, Panarese, A., additional, Del Vecchio Blanco, G., additional, Vaira, B., additional, Pellicano, R., additional, Ferrara, M., additional, Romano, M., additional, Conigliaro, R., additional, Stanghellini, V., additional, and Bazzoli, F., additional

Published
2019
Full Text
View/download PDF

35. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology

Author

Fabio Salvatore Macaluso, Ambrogio Orlando, Claudio Papi, Stefano Festa, Daniela Pugliese, Stefanos Bonovas, Claudia Pansieri, Daniele Piovani, Gionata Fiorino, Massimo Claudio Fantini, Flavio Caprioli, Marco Daperno, Alessandro Armuzzi, Lorenzo Bertani, Cristina Bezzio, Giorgia Bodini, Fabrizio Bossa, Andrea Buda, Emma Calabrese, Federica Furfaro, Salvatore Leone, Filippo Mocciaro, Sara Onali, Luca Pastorelli, Enrica Previtali, Mariabeatrice Principi, Sara Renna, Davide Giuseppe Ribaldone, Antonio Rispo, Fernando Rizzello, Simone Saibeni, Gianluca Matteo Sampietro, Edoardo Savarino, Anna Testa, Angela Variola, Angelo Viscido, Sandro Ardizzone, Livia Biancone, Maria Cappello, Fabiana Castiglione, Rachele Ciccocioppo, Michele Comberlato, Francesco Costa, Renata D'Incà, Silvio Danese, Antonio Di Sabatino, Walter Fries, Paolo Gionchetti, Giovanni Latella, Francesco Manguso, Mauro Mastronardi, Gianmichele Meucci, Monica Milla, Maria Lia Scribano, Maurizio Vecchi, Macaluso F.S., Orlando A., Papi C., Festa S., Pugliese D., Bonovas S., Pansieri C., Piovani D., Fiorino G., Fantini M.C., Caprioli F., Daperno M., Armuzzi A., Bertani L., Bezzio C., Bodini G., Bossa F., Buda A., Calabrese E., Furfaro F., Leone S., Mocciaro F., Onali S., Pastorelli L., Previtali E., Principi M., Renna S., Ribaldone D.G., Rispo A., Rizzello F., Saibeni S., Sampietro G.M., Savarino E., Testa A., Variola A., Viscido A., Ardizzone S., Biancone L., Cappello M., Castiglione F., Ciccocioppo R., Comberlato M., Costa F., D'Inca R., Danese S., Di Sabatino A., Fries W., Gionchetti P., Latella G., Manguso F., Mastronardi M., Meucci G., Milla M., Scribano M.L., and Vecchi M.

Subjects
Clinical guidelines, Biological Products, IG-IBD, Hepatology, Biologic, Gastroenterology, Biologics, GRADE, Small molecule drugs, Adalimumab, Humans, Infliximab, Colitis, Ulcerative, Inflammatory Bowel Diseases, Ulcerative, Colitis, Settore MED/12, Clinical guideline
Abstract

The management of moderate to severe ulcerative colitis has undergone significant changes over the past 15 years due to the regulatory approval of several new drugs. In particular, following the approval of the first biological, i.e. infliximab, a number of further biological drugs, such as adalimumab, golimumab, vedolizumab and ustekinumab, and small molecules, such as tofacitinib, have been approved, thus enriching the therapeutic armamentarium for ulcerative colitis. Choice of therapy must take into consideration not only the need to induce and maintain disease remission according to the patient's profile, but also age, co-morbidities, and prior treatments. To guide these decisions, the Italian Group for the Study of Inflammatory Bowel Disease has developed clinical guidelines that supersede its earlier document from 2011. These new guidelines were developed following the GRADE methodology for rating the quality of the evidence and for determining the strength of the recommendations. This article presents the methodology and results, in the form of 20 statements with commentary on the use of the five biologics and tofacitinib for managing the intestinal manifestations of active ulcerative colitis and for maintaining remission. A separate technical review reports the analyses of the evidence upon which the present recommendations are based.

Published
2022

36. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study

Author

Pugliese, D., Privitera, G., Crispino, F., Mezzina, N., Castiglione, F., Fiorino, G., Laterza, L., Viola, A., Bertani, L., Caprioli, F., Cappello, M., Barberio, B., Ricci, C., Balestrieri, P., Daperno, M., Pluchino, D., Rizzello, F., Scribano, M. L., Sablich, R., Pastorelli, L., Manguso, F., Variola, A., Di Sario, A., Grossi, L., Armuzzi, A., Ribaldone, D. G., Biscaglia, G., Buda, A., Mocci, G., Viscido, A., Di Paolo, M. C., Onali, S., Rodino, S., Coletta, M., Principi, M., Miranda, A., Amato, A., Bezzio, C., Petruzzellis, C., Mazzuoli, S., Festa, S., Sartini, A., Checchin, D., Fanigliulo, L., Gallina, S., Cesarini, M., Bodini, G., Stradella, D., Spagnuolo, R., Guidi, L., Savarino, E., Scrivo, B., Soru, P., Costa, F., Fries, W., Scaldaferri, F., Allocca, M., Pellegrini, L., Massari, A., Orlando, A., Pugliese D., Privitera G., Crispino F., Mezzina N., Castiglione F., Fiorino G., Laterza L., Viola A., Bertani L., Caprioli F., Cappello M., Barberio B., Ricci C., Balestrieri P., Daperno M., Pluchino D., Rizzello F., Scribano M.L., Sablich R., Pastorelli L., Manguso F., Variola A., Di Sario A., Grossi L., Armuzzi A., Ribaldone D.G., Biscaglia G., Buda A., Mocci G., Viscido A., Di Paolo M.C., Onali S., Rodino S., Coletta M., Principi M., Miranda A., Amato A., Bezzio C., Petruzzellis C., Mazzuoli S., Festa S., Sartini A., Checchin D., Fanigliulo L., Gallina S., Cesarini M., Bodini G., Stradella D., Spagnuolo R., Guidi L., Savarino E., Scrivo B., Soru P., Costa F., Fries W., Scaldaferri F., Allocca M., Pellegrini L., Massari A., and Orlando A.

Subjects
Crohn’s disease, Ulcerative, Antibodies, Monoclonal, Humanized, biologics (IBD), immunosuppression, ulcerative colitis, Aged, Chronic Disease, Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Gastrointestinal Agents, Inflammatory Bowel Diseases, Antibodies, Monoclonal, Pharmacology (medical), Humanized, Settore MED/12 - Gastroenterologia, Hepatology, Gastroenterology, Colitis
Abstract

Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD), but few real-life data have been reported in this population. Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients. Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017. Elderly patients (≥65 years) were matched clinically 1:2 to nonelderly patients (18–64 years); the 2 groups were followed until drug discontinuation or June 2019. Results: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients (67.6% vs. 51.4%, p=0.02). No significant difference in effectiveness was observed between elderly and nonelderly CD patients (59.4% vs. 52.4%, p=0.32). Age ≥65 years was associated with lower persistence in UC; for CD, previous exposure to anti-TNF-α agents, Charlson comorbidity index >2 and moderate-to-severe clinical activity at baseline were associated with lower persistence. There were recorded 130 adverse events, with comparable rates between the two groups. A Charlson comorbidity index >2 was associated with an increased risk of adverse events. Conclusion: Vedolizumab can be considered a safe option in elderly IBD patients. Its effectiveness in elderly UC patients may be reduced, while no age-dependent effect on effectiveness was observed in CD.

Published
2022

37. Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy

Author

Vitello, A, Grova, M, Pugliese, D, Rizzello, F, Lanzarotto, F, Lavagna, A, Caccaro, R, Cappello, M, Viola, A, Ribaldone, Dg, Principi, M, Stasi, E, Scribano, Ml, Maida, M, Soriano, A, Bezzio, C, Bodini, G, Mocciaro, F, Privitera, Ac, Simondi, D, Giuffrida, E, D'Incà, R, Ricci, C, Gionchetti, P, Armuzzi, A, Orlando, A, Daperno, M, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD, Vitello A., Grova M., Pugliese D., Rizzello F., Lanzarotto F., Lavagna A., Caccaro R., Cappello M., Viola A., Ribaldone D.G., Principi M., Stasi E., Scribano M.L., Maida M., Soriano A., Bezzio C., Bodini G., Mocciaro F., Privitera A.C., Simondi D., Giuffrida E., D'Inca R., Ricci C., Gionchetti P., Armuzzi A., Orlando A., and Daperno M.

Subjects
musculoskeletal diseases, Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Effectiveness, Young Adult, Internal medicine, Adalimumab, Medicine, Humans, Adverse effect, skin and connective tissue diseases, Colectomy, Aged, Retrospective Studies, Real-world evidence, Hepatology, business.industry, Gastroenterology, Effectivene, Retrospective cohort study, Induction Chemotherapy, Middle Aged, medicine.disease, Ulcerative colitis, Discontinuation, Clinical Practice, Treatment Outcome, Italy, Safety, Concomitant, Colitis, Ulcerative, Female, Tumor Necrosis Factor Inhibitors, business, medicine.drug
Abstract

Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.0%). At week 8, clinical responses were observed in 177 cases (46.5%) and clinical remission in 136 cases (35.7%). At 12 months, remission was observed in 128 cases (33.6%). Overall, 44 patients required colectomy, and 170 patients (44.6%) were still taking adalimumab when data were collected. Variables associated with adalimumab discontinuation were concomitant steroid treatment, severe clinical-endoscopic activity at baseline, need for adalimumab intensification and drug-related adverse events. Variables associated with colectomy were concomitant steroid treatment and high baseline C-reactive protein. Conclusion Adalimumab is safe and effective for the treatment of ulcerative colitis.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results